Solomon L, Abrams G
S Afr Med J. 1977 Aug 27;52(10):391-3.
A double-blind crossover trial of bumadizone calcium (Eumotol), a non-steroidal anti-inflammatory drug, has been carried out in 56 patients with rheumatoid arthritis. On both objective and subjective criteria bumadizone was superior to placebo and paracetamol at a statistically highly significant level (P less than 0,01). When tested against acetylsalicylic acid, bumadizone was more effective in 13 patients and less effective in 4 patients. Although this does not represent a statistically significant difference it does suggest that its anti-inflammatory and analgesic qualities are at least equal to those of salicylate in high dosages. There were no serious side-effects in the patients who received bumadizone and the drug was better tolerated than either acetylsalicylic acid or paracetamol.
对56例类风湿性关节炎患者进行了一项关于非甾体抗炎药布马地宗钙（优莫托尔）的双盲交叉试验。从客观和主观标准来看，布马地宗在统计学上具有高度显著优势，优于安慰剂和扑热息痛（P<0.01）。与阿司匹林相比，布马地宗对13例患者更有效，对4例患者效果较差。虽然这在统计学上没有显著差异，但确实表明其抗炎和镇痛特性至少与高剂量水杨酸盐相当。接受布马地宗治疗的患者未出现严重副作用，且该药物的耐受性优于阿司匹林或扑热息痛。
